Brief: MAIA Biotechnology Reports FDA Orphan Drug Designation for THIO for Treatment of Hepatocellular Carcinoma
26/04/2022 13:44
April 26 (Reuters) - Maia Biotechnology Inc MAIA.O :
* MAIA BIOTECHNOLOGY, INC. ANNOUNCES FDA ORPHAN DRUG
DESIGNATION
FOR THIO FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA (HCC)
Source text for Eikon: ID:nBw5KN2sta
Further company coverage: MAIA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Maia Biotechnology
See all newsBrief: Maia Biotechnology Says Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr In 3l Nsclc
Brief: Maia Biotechnology - To Terminate At The Market Offering Agreement Effective May 23, 2026 - SEC Filing
Brief: Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer
Brief: Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing
MAIA Biotechnology plunges after $30 million share sale